Consistently, in vitro invasion assay, we found that CBR1 inhibition using specific short interfering RNA treatment resulted in two- to three-fold increased invasion ability of HNSCC cell lines. The gene discussed is CBR1; the disease is head and neck squamous cell carcinoma.